Passardi, Alessandro |
COLORE, NCT02000050: Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma |
|
|
| Completed | 2 | 52 | Europe | FOLFOX4, Tomotherapy, TME (Total Mesorectal Excision), surgery | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Rectal Carcinoma | 03/19 | 03/19 | | |
BRICKET, NCT06578559: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC |
|
|
| Recruiting | 2 | 16 | Europe | Cetuximab, Encorafenib | Gruppo Oncologico del Nord-Ovest, Merck Sharp & Dohme LLC, Pierre Fabre Laboratories | Colorectal Cancer | 08/26 | 04/27 | | |
CombiCoR-Vax, NCT06522919: Sequential Immunochemotherapy Treatment With Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 36 | Europe | Autologous Dendritic Cell (DC) Vaccine | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer | 04/26 | 09/26 | | |
NCT02921724: Participatory Research for Fine-tuning of a 2.0 System to Optimise Home Management of Oral Cancer Therapies. |
|
|
| Active, not recruiting | N/A | 40 | Europe | TreC-Onco | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Kessler Foundation | Cancer, Oral Drug Administration | 05/21 | 05/21 | | |
| Recruiting | N/A | 100 | Europe | medication reconciliation | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Medication Reconciliation | 01/22 | 06/22 | | |
NCT04826458: Clinical Study Comparing Different Strategies to Increase Adherence to Oral Therapies in Oncohematology |
|
|
| Recruiting | N/A | 124 | Europe | TreC-Onco, electronic diary, Paper diary | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Cancer, Solid Tumor, Hematologic Malignancy, Oral Drug Administration | 05/23 | 05/23 | | |